amifostine anhydrous has been researched along with Thyroid Neoplasms in 12 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important." | 2.69 | Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. ( Bohuslavizki, KH; Brenner, W; Clausen, M; Henze, E; Klutmann, S; Mester, J, 1998) |
| "Xerostomia was graded according to WHO criteria." | 2.69 | Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. ( Bleckmann, C; Bohuslavizki, KH; Brenner, W; Clausen, M; Henze, E; Klutmann, S; Lassmann, S; Mester, J, 1999) |
| "Xerostomia was graded according to WHO-criteria." | 2.69 | Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. ( Bleckmann, C; Bohuslavizki, KH; Brenner, W; Buchert, R; Clausen, M; Henze, E; Klutmann, S; Kröger, S; Mester, J, 1999) |
| "Since differentiated thyroid cancer has an excellent prognosis, reduction of long-term side effects of high-dose radioiodine treatment (HD-RIT), i." | 2.69 | Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. ( Bohuslavizki, KH; Buchert, R; Clausen, M; Jenicke, L; Klutmann, S; Kröger, S; Mester, J, 1999) |
| "Standard treatment of differentiated thyroid cancer includes total thyroidectomy and high-dose Radioactive Iodine Therapy (RIT) for ablation of remnant thyroid tissue." | 1.51 | Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment. ( Altun, GD; Ergulen, A; Muratli, A; Serim, BD; Torun, N, 2019) |
| "Patients with well-differentiated thyroid cancer have a good prognosis but a significant chance for local recurrence." | 1.32 | Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. ( Elkins, D; Goffman, TE; Karakla, D; Mason, ME; Mendoza, A; Shaffer, B, 2004) |
| "Because differentiated thyroid cancer has a good prognosis, reduction of long-term side effects is important." | 1.30 | Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. ( Bohuslavizki, KH; Brenner, W; Clausen, M; Feyerabend, B; Henze, E; Hübner, RH; Klutmann, S; Lassmann, S; Lüttges, J; Tinnemeyer, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Auttara-Atthakorn, A | 1 |
| Sungmala, J | 1 |
| Anothaisintawee, T | 1 |
| Reutrakul, S | 1 |
| Sriphrapradang, C | 1 |
| Torun, N | 1 |
| Muratli, A | 1 |
| Serim, BD | 1 |
| Ergulen, A | 1 |
| Altun, GD | 1 |
| Ma, C | 2 |
| Xie, J | 2 |
| Chen, Q | 1 |
| Wang, G | 2 |
| Zuo, S | 2 |
| Jiang, Z | 1 |
| Mandel, SJ | 1 |
| Mandel, L | 1 |
| Mendoza, A | 1 |
| Shaffer, B | 1 |
| Karakla, D | 1 |
| Mason, ME | 1 |
| Elkins, D | 1 |
| Goffman, TE | 1 |
| Kim, SJ | 1 |
| Choi, HY | 1 |
| Kim, IJ | 1 |
| Kim, YK | 1 |
| Jun, S | 1 |
| Nam, HY | 1 |
| Kim, JS | 1 |
| Bohuslavizki, KH | 5 |
| Brenner, W | 4 |
| Klutmann, S | 5 |
| Hübner, RH | 1 |
| Lassmann, S | 2 |
| Feyerabend, B | 1 |
| Lüttges, J | 1 |
| Tinnemeyer, S | 1 |
| Clausen, M | 5 |
| Henze, E | 4 |
| Mester, J | 4 |
| Bleckmann, C | 2 |
| Kröger, S | 2 |
| Buchert, R | 2 |
| Jenicke, L | 1 |
4 reviews available for amifostine anhydrous and Thyroid Neoplasms
| Article | Year |
|---|---|
Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
Topics: Adenocarcinoma; Amifostine; Bethanechol; Humans; Iodine Radioisotopes; Pilocarpine; Randomized Contr | 2022 |
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiatio | 2009 |
Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.
Topics: Amifostine; Animals; Humans; Iodine Radioisotopes; Radiation Dosage; Radiation-Protective Agents; Sa | 2010 |
Radioactive iodine and the salivary glands.
Topics: Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiation Injuries; Radiation-Protec | 2003 |
5 trials available for amifostine anhydrous and Thyroid Neoplasms
| Article | Year |
|---|---|
Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan.
Topics: Adult; Aged; Amifostine; Cell Differentiation; Combined Modality Therapy; Cytoprotection; Female; Hu | 2008 |
Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
Topics: Adenocarcinoma, Follicular; Adult; Amifostine; Carcinoma, Papillary; Double-Blind Method; Female; Hu | 1998 |
Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Iodine Radioisotopes | 1999 |
Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Amifostine; Carcinoma, Papillary; Double | 1999 |
Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Animals; Antiemetics; Blood Pressure; Dose-Response Rela | 1999 |
3 other studies available for amifostine anhydrous and Thyroid Neoplasms
| Article | Year |
|---|---|
Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
Topics: Amifostine; Animals; Carcinoma, Papillary; Carnitine; Guinea Pigs; Injections, Intramuscular; Iodine | 2019 |
Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Chronic Disease; Fatigue; Fem | 2004 |
Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Amifostine; Animals; Carcinoma, Papillary; Case-Control Stu | 1998 |